• Pacira BioSciences, Inc. recently reported first-quarter 2026 results showing revenue of US$177.38 million, up from US$168.92 million a year earlier, while net income eased to US$2.92 million and diluted EPS to US$0.07.
• Alongside these results, the company highlighted real-world Medicare data for EXPAREL showing reduced opioid use and medical costs after outpatient hip replacements, while an activist proxy battle with DOMA Perpetual Capital Management adds a governance twist ahead of the June 2026 shareholder meeting.
• We’ll now examine how Pacira’s Q1 performance and new real-world EXPAREL data may influence its investment narrative around non-opioid pain management.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Pacira BioSciences Investment Narrative Recap

To own Pacira, you have to believe in the long term shift toward non opioid pain management and Pacira’s ability to turn that demand into profitable growth despite its dependence on EXPAREL. The latest quarter showed modest revenue growth but softer earnings, while the unfolding proxy fight with DOMA looks more like a governance overhang than a direct hit to near term product demand, though it could still influence how management executes on its pipeline and cost plans.

The new real world EXPAREL Medicare data is especially relevant here, because it directly targets the key catalyst many investors focus on: proving that non opioid options can both cut opioid use and lower total medical costs. If payers and hospitals pay attention to these findings in outpatient hip surgery, that could support broader adoption under tighter cost controls and reinforce Pacira’s case that its products fit where regulators and payers want perioperative care to go.

Yet while the clinical story looks encouraging, investors should also be aware that growing payer cost pressure and rising scrutiny of expensive pain drugs could still...

Pacira BioSciences' narrative projects $908.9 million revenue and $112.0 million earnings by 2028.

Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming Pacira’s revenue would reach about US$865 million and earnings US$97 million by 2029, so you may want to compare that more pessimistic view on tighter cost controls with how the new EXPAREL data and proxy battle could reshape both growth expectations and risk around reimbursement and pricing.

Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be worth just $29.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pacira BioSciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Pacira BioSciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pacira BioSciences' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.